MedPath

3D gait analysis and L-DOPA in Dravet syndrome.

Phase 4
Recruiting
Conditions
Dravet syndrome(severe myoclonic epilepsy in infant)
Dravet syndrome, severe myoclonic epilepsy in infant
D004831
Registration Number
JPRN-jRCTs041190116
Lead Sponsor
atsume Jun
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

1.clinically diagnosed with Dravet syndrome
2.6 years or older, exhibiting gait deviations
3.adequately participation to 3D gait analysis with independent walk
4.written informed consent

Exclusion Criteria

1.unnable to participate to 3D gait analysis adequately
2.past prescription of L-DOPA
3.contraindication for L-DOPA
4.severe general complications
5.cannnot obtain informed consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Gait Deviation Index at before and after L-DOPA administration
Secondary Outcome Measures
NameTimeMethod
Gait Profile Score, gait ability and QOL assessed by questionnaire at before and after L-DOPA administration<br>UPDRS score, FMDRS score<br>functional connectivities of basal ganglia network before and after L-DOPA adminiatration
© Copyright 2025. All Rights Reserved by MedPath